The North America travel vaccines market size reached US$ 1.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2027, exhibiting a growth rate (CAGR) of 6.89% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Vaccines are defined as biological preparations that protect the human body against severe and potentially deadly diseases. They generally consist of an agent made from the surface protein, toxins, weakened or killed forms of the disease-causing microorganisms. Vaccination enables the body to produce antibodies, which provide a shield in case the person is exposed to the disease. For travel vaccines, also known as travel immunizations, travelers are vaccinated 4 to 6 weeks before the journey. These can be differentiated between recommended and required vaccines. Wherein, required vaccines are essential for the individual to get before entering a country. However, recommended vaccines are those which the traveler may need because of a potential infection threat in the country or a part of that country. Some of the most common vaccine-preventable, travel-related diseases include influenza, meningitis, rabies, tick-borne encephalitis, polio, diphtheria, tetanus, pertussis, etc.

North America travel vaccines market is currently being driven by several factors. One of the key factors driving the demand of travel vaccines is their ability to prevent the risk of disease epidemic. Moreover, vaccination provides immunity to individuals, travelling to places where there is a high risk of exposure or contracting a specific disease. As a result, governments in the region have mandated vaccination before visiting certain destinations with a high prevalence of infectious diseases. Other factors driving the demand of travel vaccines in the region include rising number of travelers, government initiatives, technological advancements such as combination vaccines and needle free techniques, etc.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the North America travel vaccines market report, along with forecasts at the regional and country level from 2022-2027. Our report has categorized the market based on composition and disease.

Key Regions Analysed
United States
Canada
Mexico

Analysis for Each Country

Market by Composition
Mono Vaccines
Combination Vaccines

Market by Disease
Hepatitis A
DPT
Yellow Fever
Typhoid
Hepatitis B
Measles and Mumps
Rabies
Meningococcal
Varicella
Japanese Encephalitis
Others

Value Chain Analysis
Key Drivers and Challenges
Porters Five Forces Analysis
PESTEL Analysis
Government Regulations
Competitive Landscape
Competitive Structure
Key Player Profiles

Key Questions Answered in This Report
1. What was the size of the North America travel vaccines market in 2021?
2. What is the expected growth rate of the North America travel vaccines market during 2022-2027?
3. What are the key factors driving the North America travel vaccines market?
4. What has been the impact of COVID-19 on the North America travel vaccines market?
5. What is the breakup of the North America travel vaccines market based on the composition?
6. What is the breakup of the North America travel vaccines market based on the disease?
7. What are the key regions in the North America travel vaccines market?